DK0742721T3 - Fremgangsmåder til forlænget suppression af humoral immunitet - Google Patents

Fremgangsmåder til forlænget suppression af humoral immunitet

Info

Publication number
DK0742721T3
DK0742721T3 DK94926660T DK94926660T DK0742721T3 DK 0742721 T3 DK0742721 T3 DK 0742721T3 DK 94926660 T DK94926660 T DK 94926660T DK 94926660 T DK94926660 T DK 94926660T DK 0742721 T3 DK0742721 T3 DK 0742721T3
Authority
DK
Denmark
Prior art keywords
methods
antagonist
humoral immunity
prolonged suppression
suppression
Prior art date
Application number
DK94926660T
Other languages
English (en)
Inventor
Randolph J Noelle
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26813793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0742721(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College filed Critical Dartmouth College
Application granted granted Critical
Publication of DK0742721T3 publication Critical patent/DK0742721T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DK94926660T 1993-09-02 1994-09-02 Fremgangsmåder til forlænget suppression af humoral immunitet DK0742721T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11599093A 1993-09-02 1993-09-02
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
PCT/US1994/009872 WO1995006480A1 (en) 1993-09-02 1994-09-02 Methods of prolonged suppression of humoral immunity

Publications (1)

Publication Number Publication Date
DK0742721T3 true DK0742721T3 (da) 1999-11-01

Family

ID=26813793

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94926660T DK0742721T3 (da) 1993-09-02 1994-09-02 Fremgangsmåder til forlænget suppression af humoral immunitet

Country Status (14)

Country Link
EP (1) EP0742721B1 (da)
JP (1) JP2840131B2 (da)
CN (1) CN1137726C (da)
AT (1) ATE179616T1 (da)
AU (3) AU7643094A (da)
DE (1) DE69418349T2 (da)
DK (1) DK0742721T3 (da)
ES (1) ES2134954T3 (da)
FI (1) FI106927B (da)
GR (1) GR3030762T3 (da)
IL (1) IL110852A (da)
NO (1) NO321037B1 (da)
NZ (1) NZ273208A (da)
WO (1) WO1995006480A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2408691A1 (en) 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
CA2994825A1 (en) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0897983B1 (en) * 1991-10-25 2003-05-07 Immunex Corporation Antibody against CD40-L
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU655349B2 (en) * 1992-02-17 1994-12-15 Kenji Nakamura An antibacterial porous inorganic capsule and a process for producing the same

Also Published As

Publication number Publication date
DE69418349T2 (de) 1999-09-09
NO960863L (no) 1996-04-30
GR3030762T3 (en) 1999-11-30
DE69418349D1 (de) 1999-06-10
JP2840131B2 (ja) 1998-12-24
FI960979A (fi) 1996-04-30
NO321037B1 (no) 2006-03-06
EP0742721A1 (en) 1996-11-20
AU734853B2 (en) 2001-06-21
NZ273208A (en) 2000-12-22
NO960863D0 (no) 1996-03-01
FI960979A0 (fi) 1996-03-01
JPH09502184A (ja) 1997-03-04
AU2004240180A1 (en) 2005-01-27
WO1995006480A1 (en) 1995-03-09
AU7643094A (en) 1995-03-22
AU2004240180B2 (en) 2007-08-09
ES2134954T3 (es) 1999-10-16
IL110852A0 (en) 1994-11-28
FI106927B (fi) 2001-05-15
IL110852A (en) 1999-05-09
CN1137726C (zh) 2004-02-11
AU1422099A (en) 1999-04-01
ATE179616T1 (de) 1999-05-15
CN1137758A (zh) 1996-12-11
EP0742721B1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
DK0742721T3 (da) Fremgangsmåder til forlænget suppression af humoral immunitet
DK0724432T3 (da) Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner
GR3030568T3 (en) Inducing cytotoxic t lymphocyte responses.
DE122010000015I1 (de) Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
NZ510544A (en) Novel adjuvant for subunit or component vaccines
DK0596032T4 (da) Induktion af cytotoksiske T-lymfocytsvar
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
PT584348E (pt) Vacina genetica para virus da imunodeficiencia
ATE326231T1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
DE69128782D1 (de) Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff
DE3684552D1 (de) Organosol von fluor enthaltenden copolymerteilchen.
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
DK0882132T3 (da) Et kombineret humant cytomegalovirus-antigen og anvendelse heraf
PT1021196E (pt) Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenio
IT8368342A0 (it) Procedimento e dispositivo per lapreparazione di bevande gassate particolarmente per uso in ambiente domestico
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
DK0929315T3 (da) Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse
ES1025386Y (es) Colchon combinado de lamas y muelles con adaptador lumbar.
AU2001297869A1 (en) Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
ITMI932114A0 (it) Uso di una composizione elastometrica a base di un terpolimero etilene-propilene-etilidennorbornene per la costruzione di supporti antisismici
CA2246802A1 (en) A human cytomegalovirus combined antigen and its use
NZ334582A (en) Polyprotein construct of a papillomavirus
DE3779444T2 (de) Impfstoff gegen herpes simplex.